Interim report January – June 2012
Continued positive sales development, +88% in the quarter and closing of successful new share issue.January – June 2012 · Global Net sales grew by 82% to SEK 76.0m (41.8). Adjusted for currency fluctuations, net sales rose by 75% Year over Year (YoY) · The worldwide number of NIOX MINO® repeat tests sold increased by a total of 50% and for clinical use in the US by 75% · The loss after tax amounted to SEK 80.5m (56.2), corresponding to a loss per share before and after dilution of SEK 0.7 (0.5). The increased loss was primarily driven by increased commercial and reimbursement